“…The present approach to analyze blood samples collected from patients during MTH at 32°C and 37°C allowed a more accurate assessment of cooling-induced coagulation impairment. The finding that TEG results may be affected by the in vitro temperatures have already been confirmed in some studies [15,28,31,43], while in other studies it was considered insignificant [19,44]. However, in the largest randomized clinical trial conducted to date by Nielsen et al [45], it was shown that there were no differences in risk of death and neurological outcome between group with 33°C (MTH) vs. 36°C of targeted temperature management (TTM) This takes into consideration new ILCOR guidelines which recommend both therapies -MTH or targeted temperature management are nowadays the standard procedures in OHCA patients.…”